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Oxidative stress and aggregation of the protein α-synuclein are thought to be key 
factors in Parkinson’s disease.  Previous work shows that cytochrome c plus 
H2O2 causes tyrosine-dependent in vitro peroxidative aggregation of proteins, 
including α-synuclein.  Herein, I detail a method for monitoring α-synuclein and 
cytochrome c in a variety of experiments.  Using this system, I examine the role 
of each of α-synuclein’s four tyrosine residues and how the protein’s 
conformation affects covalent oxidative aggregation.  When α-synuclein adopts a 
collapsed conformation, tyrosine 39 is essential for wild-type-like covalent 
aggregation.  This lone N-terminal tyrosine, however, is not required for wild 
type-like covalent aggregation in the presence of a denaturant or when α-
synuclein is present in non-covalent fibrils.  I also show that pre-formed oxidative 
aggregates are not incorporated into non-covalent fibrils.  These data provide 
insight as to how dityrosine may be formed in Lewy bodies seen in Parkinson’s 
disease.  Additionally, I detail the progress made toward studying the toxicity of 
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Chapter 1 Introduction 
  Parkinson’s disease, the second most common neurodegenerative 
disorder (1), affects over 1.5 million people in the United States, with over 60,000 
new diagnoses each year (2). Parkinson’s disease manifests itself in three ways: 
parkinsonism, death of dopaminergic (DAergic) neurons with a resulting 
decrease in dopamine levels, and the formation of Lewy bodies (3). 
Parkinsonism is a syndrome that encompasses physical symptoms such as 
bradykinesia (slowed movement), tremor, rigidity, and postural instability.  These 
symptoms arise after the death of 60% - 70% of the DAergic cells in the 
substantia nigra pars compacta (4), which causes an 80% drop in dopamine 
levels.  Lewy bodies are protein inclusions in the remaining neurons.  These 
inclusions have many components, including cytoskeletal proteins such as 
tubulin (5) and microtubule-associated protein-2 (6), lipids, neurofilaments (7), 
and cytochrome c (8).  The main component of Lewy bodies is α-synuclein (9), 
much of which is covalently cross-linked.  The disease has three main causes: 
environmental, genetic, and idiopathic (also known as age-related). 
1.1 Causes of Parkinson’s disease 
 1.1.1 Environmental  
  In 1983, the first chemical agent to cause permanent parkinsonism in 
humans was identified (10).  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
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 (MPTP) is a byproduct of the incorrect synthesis of 1-methyl-4-phenyl-4-
propionoxy-piperidine (MPPP), an opioid similar to morphine (Figure 1.1).  MPTP 
readily crosses the blood brain barrier (11), where it is oxidized to 1-methyl-4-
phenylpyridinium (MPP+, Figure 1.1) by monoamine oxidase B (12).  MPP+ then 
enters DAergic cells via the dopamine transporter, where it is trafficked to the 
mitochondria and inhibits complex I of the electron transport chain (13).  This 
inhibition causes the generation of reactive oxygen species (ROS) such as 
superoxide (O2-).  To date, MPTP is the only chemical agent that reproduces the 
three hallmarks of Parkinson’s disease in animal models (14-16) and causes 
permanent parkinsonism in humans. 
  Paraquat, a herbicide, has a structure similar to MPP+ (Figure 1.2), and 
has therefore been investigated as a possible parkinsonian toxin.  Paraquat 
mimics many of the symptoms of Parkinson’s in animal models through complex 
I (17) and complex III (18) inhibition.  When complex III is inhibited, it can leak 
excess electrons to oxygen, resulting in the generation of O2- (19).  Paraquat is 
an especially potent ROS generator because it undergoes redox cycling using 
various enzymes in the cell (including complex I and complex III) to generate O2- 
and regenerate the paraquat molecule (Figure 1.2).  While no confirmed cases of 
paraquat-induced Parkinson’s disease have been reported, epidemiological 
evidence suggests a higher likelihood of the disease in individuals exposed to 
paraquat in agricultural settings (20, 21). 
  Several other pesticides (Figure 1.3) have also been used to replicate 
Parkinson’s in animal models, although none of them reproduce all three of the 
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hallmarks seen in humans.  The insecticide rotenone elucidates symptoms via 
complex I inhibition (22), but due to its short half life in soil and water (23) and the 
efficiency which the liver breaks it down (14), it is unlikely to cause parkinsonism 
in humans.  Dieldrin, an insecticide, inhibits complex III (24), causing the 
generation of O2- and cytochrome c release (25).  No causal relationship has 
been demonstrated in humans, but postmortem brain samples of Parkinson’s 
disease sufferers show an elevated level of dieldrin compared to cohort samples 
(26).  The fungicide maneb, however, has been shown to cause permanent 
parkinsonism in humans (27) by complex III inhibition (28). 
  Regardless of the symptoms they induce in animals or humans, all five of 
these chemical agents work by inhibition of electron transfer in the mitochondria 
and the generation of ROS, and their properties are summarized in Table 1.1. 
 1.1.2 Genetic  
  While only 5-10% of Parkinson’s disease sufferers have a monogenic form 
of the disease (29), genetic causes have been the most widely studied because 
they can offer simple insight into the mechanisms of this complicated disease.  
To date, eleven genes have been identified which, through Mendelian inheritance 
or spontaneous mutation, either cause Parkinson’s disease or increase disease 
susceptibility (Table 1.2). 
  α-Synuclein was the first such gene identified, yet its cellular function 
remains unclear.  It appears to regulate dopamine homeostasis by trafficking the 
dopamine transporter away from the cell surface (30) using the microtubule 
network (31).  α-Synuclein’s most striking characteristic, in vivo and in vitro, is its 
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propensity to aggregate (32).  This aggregation propensity is most affected by 
protein concentration and conformation.  Duplications or triplications of the gene 
cause earlier onset and increased severity of symptoms in a dose-dependent 
manner (33-35), and mutations in α-synuclein’s promoter region are a risk factor 
for the idiopathic disease.  The three identified point mutations, A30P, A53T, and 
E46K, all increase the propensity of the affected protein to aggregate in vitro (36, 
37), and impair the proteasome system in vivo (38).  Additionally, post-
translational modifications of the C-terminus of α-synuclein, such as oxidation or 
phosphorylation, disrupt the protein’s conformation and lead to increased 
aggregation (39, 40). 
  Five other Parkinson’s disease-associated proteins are involved in protein 
degradation.  Ubiquitin carboxyl-terminal hydrolase L1, UCH-L1, is a ubiquitin 
hydrolase and E3 ligase which plays a dual role in Parkinson’s.  The I93M 
mutation causes autosomal-dominant late-onset Parkinson’s (41) by increasing 
ligase function, which decreases the pool of ubiquitin by causing an accumulation 
of ubiquitinated α-synuclein (42).  Conversely, the S18Y mutation has normal 
hydrolase function but decreased ligase function (42).  This mutation facilitates 
protein degradation and ubiquitin recycling, which protects against Parkinson’s.  
Parkin is another E3 ligase involved in Parkinson’s disease, in which mutations 
confer a loss of ligase function (43-45) causing autosomal-recessive juvenile and 
early-onset Parkinson’s disease (44).  Multiple protein targets of parkin have 
been identified, including the cytoskeletal proteins α- and β-tubulin (46), which 
are found in Lewy bodies, and the dopamine transporter (47).  Interestingly, 
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parkin interacts with a glycosylated form of α-synuclein (48) and can ameliorate 
the cytotoxic effects of α-synuclein overexpression (49, 50).  Parkin can also 
deactivate synphilin-1 (51), which interacts with α-synuclein to promote protein 
inclusion formation.  The inheritable R621C mutation of synphilin-1 does not 
disrupt its interaction with parkin or α-synuclein, but leads to a decrease in 
inclusion formation (52).  Two other Parkinson’s-associated proteins are also 
involved in lysosomal protein degradation.  Atp13A2’s normal cellular function is 
unclear, but in autosomal-recessive juvenile and early-onset Parkinson’s disease 
(53, 54) it is degraded by the proteasome system instead of being inserted into 
the lysosomal membrane where it normally functions (55).  Mutations in β-
glucocerebrosidase, a lysosomal glucose metabolism protein, cause the 
lysosomal storage disorder Gaucher’s (56) disease, and confer a susceptibility to 
Parkinson’s disease (57, 58) through an unknown mechanism. 
  Similar to chemical causes of Parkinson’s, mitochondrial function and 
oxidative stress play a role in genetic causes as well.  PTEN induced putative 
kinase 1, pink1, is a mitochondrial kinase that acts on several protein targets.  
Mutations in pink1 cause autosomal-recessive early-onset Parkinson’s disease 
(59).  Inactivation of pink1 in vivo causes oxidative stress-induced apoptosis (60) 
and pink1 mutations cause respiratory chain malfunctions in patients with 
Parkinson’s (61).  Pink1 can phosphorylate parkin, which is then trafficked to the 
mitochondria, where it induces oxidative stress (62, 63) and causes 
mitochondrial dysfunction.  The mitochondrial serine protease omi is also a 
phosphorylation target of pink1 (64), and this phosphorylation increases omi’s 
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proteolytic activity (64).  Insufficient evidence exists to suggest that the G399S 
and A141S omi mutations are associated with Parkinson’s disease in humans 
(65, 66), but these mutations, and omi deletion, cause parkinsonism in mouse 
models (67, 68).  While the link between dj-1 mutation and autosomal-recessive 
early-onset Parkinson’s disease (69) has been established, its function is less 
clear.  It is most likely involved in oxidative stress protection because it sustains 
mitochondrial complex I in vitro (70) and dj-1 null mice are more sensitive to 
MPTP-induced parkinsonism (71). 
  The least-understood class of Parkinson’s disease-associated proteins is 
those involved in cytoskeletal maintenance.  Tau is the major neuronal 
microtubule-associated protein and binds tubulin to promote assembly of the 
cytoskeleton (72).  In Alzheimer’s pathology, hyper-phosphorylation causes tau 
to aggregate into filaments (73-76), the concentration of which is directly 
proportional to the severity of dementia (77).  Hyper-phosphorylated tau cannot 
bind tubulin (78) and disrupts microtubules (79, 80).  Recently, genomic 
screening has revealed single nucleotide polymorphisms [all of which are linked 
to the H1 haplotype (81)] associated with a higher Parkinson’s disease risk (82).  
This association implies some common links between the two neurodegenerative 
disorders.  Mutations in leucine-rich repeat kinase 2, LRRK2, are the most 
frequent genetic cause of Parkinson’s disease, accounting for 3.6% of sporadic 
cases (83) and 10% of familial cases (84).  Its cellular function is unknown, but 
the protein has numerous domains (85) in addition to a kinase domain, including 
a WD40 repeat (coordinates multi-protein complexes), a Ras/GTPase domain 
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(cytoskeleton rearrangement), and a leucine-rich repeat domain.  Because it is 
abundantly expressed throughout the central nervous system (86), LRRK2 most 
likely performs a basic cellular function, possibly cytoskeletal remodeling using 
the GTPase domain.  Conversely, the kinase domain appears to be most 
important in Parkinson’s because some mutations confer a toxic increase of 
kinase function in vitro (87).  Interestingly, for the G2019S mutation, disease 
penetrance increases from 17% at age 50 to 85% at age 70 (88).  This increase 
suggests that LRRK2 mutations are not a direct cause of Parkinson’s, but 
interact with other age-related cellular processes to confer an increased risk of 
disease. 
 1.1.3 Age-Related  
  Age is the most common risk factor in Parkinson’s disease (89).  As seen 
in Figure 1.4, the rate of incidence increases exponentially starting at age 50 
(90).  Interestingly, advancing age not only increases the risk of developing the 
disease, but also increases the rate of disease progression.  An older age of 
onset has been correlated to a faster rate of progression for cognitive (91), motor 
(92, 93), and gait and postural (94) symptoms.  These data indicate a synergy 
between Parkinson’s disease and the normal aging process. 
  While the aging process occurs in every living organism, the mechanisms 
that lead to aging are not fully understood.  Possible sources include 
mitochondrial mutations (95), chromosomal damage through shortened 
telomeres (96), inappropriate cross-linking of proteins and other cellular 
components (97), and a disruption of cellular signaling leading to senescence 
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(98).  Oxidative stress is most likely an underlying cause in all these 
mechanisms, leading to the “oxidative stress theory” of aging (99), which posits 
that an increased burden of ROS leads to changes in cellular function and, 
ultimately, death. 
 
  There are many causes of Parkinson’s disease which may act alone or in 
concert.  Whether induced by chemical agents, genetic factors, or general 
aspects of aging, increased oxidative stress plays a key role in the disease. 
1.2 α-Synuclein 
  α-Synuclein is a 140-amino acid, intrinsically disordered protein (100) with 
three distinct regions (Figure 1.5A).  The N-terminal region is positively charged, 
the hydrophobic core (also known as the non-amyloid component) comprises 
residues 61-90, and the C-terminal region is negatively charged.  α-Synuclein 
also has four unevenly distributed tyrosine residues, one (Y39) near the N-
terminus and three (Y125, Y133, and Y136) near the C-terminus.  Although 
disordered, the protein adopts a compact state (26-29) wherein the charged 
termini collapse around the hydrophobic core (Figure 1.5B).  Multiple factors are 
involved in the mechanism of Parkinson’s disease, but both non-covalent and 
covalent aggregation of α-synuclein are thought to play a key role (101). 
1.2.1 Lewy Bodies 
Lewy bodies in the substantia nigra are one of the hallmarks of 
Parkinson’s disease and they form due to the aggregation of α-synuclein.  The 
pathway of Lewy body formation is: 
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α-synuclein  monomer  → oligomer/protofibril → amyloid fibril → Lewy body 
Some evidence suggests that Lewy bodies are toxic to neurons, either by 
up-regulating apoptotic factors (102) or impairing the ubiquitin-proteasome 
system (103), or simply by providing a physical barrier to normal cell trafficking.  
However, the bulk of the biochemical evidence suggests that it is actually an 
intermediate species, specifically the annular or ring-shaped form of the 
protofibril, which is most toxic to neurons.  Two of the α-synuclein mutations 
associated with Parkinson’s disease, A30P and A53T, both promote the 
conversion of monomer to protofibril, and A30P also disfavors the conversion of 
protofibril to fibril (104).  Protofibrils can take on an annular conformation, 
especially when associated with lipid vesicles (105) or brain-derived membranes 
(106).  Annular protofibrils can permeate membranes, both α-synuclein 
associated with lipid vesicles (105) and the Alzheimer’s protein Aβ associated 
with PC12 cells (107).  Pre-fibrillar amyloid aggregates of proteins not associated 
with any known disease are also toxic to cultured cells (108), suggesting that the 
intermediate protofibril form is a generic cell toxin. 
While the main component of Lewy bodies is non-covalently-aggregated 
α-synuclein, covalent aggregation may also play a role in Lewy body 
development.  Nitrotyrosine, a sign of nitrative stress, has been identified as a 
component of Lewy bodies (109).  The oxidative stress marker dityrosine has 
also been detected in brain hydrolysates of murine models of Parkinson’s 
disease (110).  Understanding the process of Lewy body formation and the 
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interplay between non-covalent and covalent aggregation in that process is one 
of the keys to understanding Parkinson’s disease. 
 1.2.2 Non-covalent Aggregation 
  The α-synuclein fibrils observed in patients with Parkinson’s are linear rods, 
5-10 nm in diameter, much like those seen in other amyloid diseases (111).  The 
fibrils comprise insoluble cross-β-sheets, and their growth in vitro exhibits a 
sigmoidal time dependence (112) as seen in Figure 1.6.  Prior to fibril growth 
there is a lag, the length of which depends on factors such as protein 
concentration and pH (113). This lag phase also indicates that the formation of 
fibrils is a nucleation-dependant process (114, 115). Kinetic analysis of fibril 
formation reveals that the required nucleus is only a single α-synuclein molecule 
(111), meaning that the natively disordered monomer must undergo a folding 
event before being converted into protofibrils. Following the lag is a period of 
elongation in which fibril concentration increases exponentially and plateaus 
(111). Fibril growth can be monitored by using thioflavin-T, which experiences a 
shift in its excitation spectrum when bound to β-sheets in fibrils, allowing it to be 
selectively excited at 442 nm (116). 
 1.2.3 Covalent Aggregation 
  Oxidative stress and α-synuclein play some role in Parkinson’s disease.  
Fenton-chemistry based oxidation systems (i.e., a transition metal plus H2O2) 
have been used extensively in vitro in attempts to reproduce in vivo covalent 
aggregation of α-synuclein.  This mechanism was initially supported by the 
observation that metals accelerate the fibrillization of α-synuclein (117), but these 
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systems are not accurate mimics (118, 119).  For instance, although dityrosine 
(tyrosines with a covalent bond between the 3/5 carbon atoms) is observed in the 
MPTP Parkinson’s disease model, the covalent aggregation induced by several 
Fenton chemistry systems is tyrosine-independent (119).  In fact, the HO  
generated by Cu2+ plus H2O2 impedes dityrosine formation in the Alzheimer’s 
disease protein, Aβ (118).   
  The cytochrome c/H2O2 oxidation system (120), referred to here as the 
peroxidative system, is another model based on possible cellular mechanisms.  
In times of oxidative stress, ROS are produced in the mitochondria.  Cytochrome 
c and ROS can leak into the cytosol (121), possibly aided by pores in the 
mitochondrial membrane formed by α-synuclein (122).  This system is a better 
model for α-synuclein covalent aggregation for two reasons.  First, the 
peroxidative system causes tyrosine-dependent covalent aggregation of α-
synuclein (123), similar to the dityrosine seen in murine models of Parkinson’s 
disease. Second, the peroxidative system causes the direct transfer of a free 
radical from cytochrome c to the acceptor protein (124, 125) without a HO  
intermediate.   
 
  Studies of environmental, genetic, and age-related causes of Parkinson’s 
disease reveal that both the process of oxidative stress and the aggregation of α-
synuclein play key roles in the pathogenesis of the disease.  As demonstrated 
above, much research has been done on each of these processes separately, 
but little is known about their interaction in Parkinson’s disease.  My research has 
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sought to address this disparity by answering two questions.  What is the role of 
each of α-synuclein’s tyrosines in the process of oxidative aggregation, and at 
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Table 1.1 Chemicals that cause parkinsonism   
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locus gene protein function inheritance onset 
PARK1/ 















n. a. SNCAIP synphillin-1 interacts with α-synuclein   AD late 








u. k. u. k. 
PARK6 PINK1 PTEN induced putative kinase 1 
mitochondrial 
kinase AR early 










n. a. TAU tau microtubule assembly u. k. u. k. 






Table 1.2 Genetic causes of Parkinson’s disease.  
AD = autosomal-dominant, AR = autosomal-recessive, n. a. = not applicable, 





Figure 1.4 Incidence rate of Parkinson’s disease in Olmsted County, 






































Figure 1.5 α-Synuclein structure and conformation.  A schematic 
representation of α-synuclein’s primary structure showing relevant regions, net 
charges, and position numbers (A), and a cartoon of its collapsed conformation 
(B). The positions of the tyrosine residues are indicated in green. 
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Chapter 2 Gene Construction and Protein Expression, 
Purification, and Fluorescent Labeling of Wild-Type and 
Variant Recombinant Human α-Synuclein and 
Cytochrome c 
Reproduced in part with permission from Biochemistry. Copyright 2008 American 
Chemical Society 
2.1 Introduction 
Western blot antibody staining has traditionally been used to detect α-
synuclein covalent aggregation (1-4). This technique, however, has several 
limitations.  First, proteins must be transferred from the poly-acrylamide gel into a 
nitrocellulose or polyvinylidene fluoride membrane.  Because the α-synuclein 
aggregation reaction encompasses protein species from 12 to over 200 kDa, 
different transfer conditions must be used for different areas of the gel.  This 
situation often leads to inconsistencies in the appearance of the protein bands in 
the two halves of the transfer.  Second, the primary antibodies may not recognize 
all covalently aggregated species with the same sensitivity, leading to a 
disconnection between the intensity and the amount of protein aggregate in each 
band.  Last, both α-synuclein and cytochrome c are used in the covalent 
aggregation reaction and both proteins be monitored.  Since antibody staining
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does not allow simultaneous visualization of the two proteins, the membrane 
must be probed for α-synuclein, stripped, and re-probed for cytochrome c.  This 
process can take up to four days.  To overcome these obstacles, I developed a 
method for fluorescently labeling each protein before the covalent aggregation 
process.  This allows both proteins to be visualized in the polyacrylamide gel, 
maintains the correlation between band intensity and amount of protein, and 
facilitates the completion of multiple experiments within a single day. 
2.2 Materials and Methods 
2.2.1 Preparation of Mutant Recombinant Human α-Synucleins and 
Cytochrome c 
The wild-type α-synuclein (5), human cytochrome c (6) and the no-tyrosine 
α-synuclein mutant (1) were used as described. Twenty-five additional human α-
synuclein mutants in the pT7-7 vector were created by using a site-directed 
mutagenesis kit (QuickChange, Stratagene, La Jolla, CA).  Mutants with one, 
two, or three tyrosine codons converted to phenylalanine codons were created 
with the following forward primers from the Nucleic Acid Core Facility in the UNC 
Lineberger Cancer Center (nucleotide changes are underlined): 
Y39F unknown 
Y125F 5’ CCTGACAATGAGGCTTTTGAAATGCCTTCTGAG 3’ 
Y133F 5’ CTTCTGAGGAAGGGTTTCAAGACTACGAACC 3’ 
Y136F 5’ GCCTTCTGAGGAAGGGTACCAAGACTTCGAACCTG 
AAGCCTAAC 3’ 




Valine-to-cysteine mutations were introduced in the wild-type α-synuclein 
construct, the tyrosine-combination mutants, and the wild-type human 
cytochrome c construct for labeling purposes.  Using the following forward 
primers, all α-synucleins had valine 3 mutated to cysteine, and an additional wild-
type construct was generated with valine 66 mutated to cysteine: 
V3C 5’ GGAGATATACATATGGATTGCTTCATGAAAGGACTTTCAA 3’ 
V66C 5’ CAAAGAGCAAGTGACAAATTGCGGAGGAGCAGTGGTGACG 3’ 
Using the following forward primer, the wild-type human cytochrome c construct 
had lysine 39 mutated to cysteine: 
K39C 5' CTGTTCGGCCGCTGCACGGGCCAGGC 3' 
All nucleotide sequences were confirmed by the UNC Automated DNA 
Sequencing Facility. 
2.2.2 Growth, Purification, and Storage of Wild-Type and Variant 
Recombinant Human α-Synucleins and Cytochromes c 
Wild-type and mutant α-synucleins were transformed into BL21 E. coli 
(Invitrogen, Carlsbad, CA).  A single colony was used to inoculate 20 mL of Miller 
Luria Broth (Fisher Scientific, Fair Lawn, NJ) supplemented with 100 mg L-1 
ampicillin (LBamp), and the resulting culture was grown at 37 C with shaking 
overnight.  The overnight culture was used to inoculate an additional 1L of LBamp, 
which was then grown at 37 C with shaking until it reached an optical densityat 
600 nm (O.D.600) of 0.6-0.8.  The culture was then induced with isopropyl β-D-1-
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thiogalactopyranoside (IPTG) to a final concentration of 1 mM.  After 4 h, the 
cells were harvested via centrifugation at 4,500 g for 30 min and stored at -20 C. 
The cells were resuspended in 20 mL of lysis buffer per liter of culture (20-
mM Tris, pH 8.0; 1-mM ethylenediamine-tetraacetic acid [EDTA]; 1-mM phenyl-
methylsulphonyl fluoride [PMSF, Pierce, Rockford, IL]; 1-mM dithiothreitol [DTT, 
only for V3C or V66C variants]).  After sonication (Sonic Dismemberator, Fisher 
Scientific, Fair Lawn, NJ) for 5 min at a 70% duty cycle, the cells were boiled for 
30 min then centrifuged at 20,200 g for 30 min.  For the V3C or V66C variants, 
the resulting supernatant was supplemented with DTT to a final concentration of 
1M.  All variants were subjected to a 10 g L-1 streptomycin sulfate cut to 
precipitate nucleic acids then centrifuged at 20,200 g for 30 min. The resulting 
supernatant was subjected to a 361 g L-1 (NH4)2SO4 cut to precipitate α-
synuclein then centrifuged at 20,200 g for 30 min.  The protein pellet was 
resuspended in 20 mL of buffer (20-mM Tris, pH 8.0, 1-mM DTT [only for V3C or 
V66C variants]) and dialyzed (SnakeSkin, 10,000 MWCO, Pierce) into 2 L of the 
same buffer at 4 C overnight.  The protein was further purified via 
chromatography using a HiLoad 16/10 Q Sepharose High Performance column 
(GE Healthcare, Uppsala, Sweden) in dialysis buffer with a linear gradient from 
0-M to 1-M NaCl.  Fractions containing pure α-synuclein (as determined by 
Coomassie-stained sodium dodecyl sulfate polyacrylamide gel electrophoresis 
[SDS-PAGE]) were combined and dialyzed (SnakeSkin, 10,000 MWCO) into 
water at 4 C overnight.  The protein concentration was determined with the 
Lowry method (7) (Modified Lowry Protein Assay Kit, Pierce) with human 
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recombinant cytochrome c (6) as a standard. After purification, proteins were 
aliquoted and lyophilized for storage at -80 C. 
Wild-type and mutant cytochromes c were transformed into BL21 E. coli.  
A single colony was used to inoculate 50 mL of terrific broth (12 g L-1tryptone, 24 
g L-1 yeast extract, 5% glycerol, 12.6 g L-1 KH2PO4, 2.3 g L-1 K2HPO4) 
supplemented with 100 mg L-1 ampicillin (TBamp).  The resulting culture was 
grown at 37 C with shaking overnight.  The overnight culture was used to 
inoculate an additional 1L of TBamp, which was then grown at 37 C with shaking 
for 24 - 48 h. The cells were harvested via centrifugation at 4,500 g. 
The cells were resuspended in 20 mL of lysis buffer per liter of culture (20-
mM NaH2PO4, pH 7.4; 1-mM EDTA; 1-mM PMSF; 1-mM DTT [K39C variant 
only]).  After four rounds of sonication for 5 min at a 50% duty cycle, the cells 
were centrifuged at 20,200 g for 30 min.  The resulting supernatant was 
subjected to a 10 g L-1 streptomycin sulfate cut to precipitate nucleic acids then 
centrifuged at 20,200 g for 30 min. The resulting supernatant was subjected to a 
350 g L-1 (NH4)2SO4 cut to precipitate unwanted proteins then centrifuged at 
20,200 g for 30 min.  The cytochrome c supernatant was dialyzed (SnakeSkin, 
10,000 MWCO) into 10 L of water (with 1-mM DTT for K39C variant) at 4 C 
overnight.  The protein was further purified via chromatography using a HiLoad 
16/10 SP Sepharose High Performance column (GE Healthcare) in buffer (20-
mM NaH2PO4, pH 7.4; 1-mM DTT [K39C variant only]) with at linear gradient 
from 0-M to 1-M NaCl.  Fractions containing pure cytochrome c (as determined 
by Coomassie-stained SDS-PAGE) were combined and dialyzed (SnakeSkin, 
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10,000 MWCO) into water at 4 C overnight.  Protein concentration was 
determined from the absorbance at 410 nm by using a molar extinction 
coefficient of 106.1 mM-1 cm-1(8). After purification, proteins were aliquoted and 
lyophilized for storage at -80 C. 
2.2.3 Alexa Fluor Labeling of Wild-Type and Variant Recombinant 
Human α-Synucleins and Cytochrome c 
Sixty nmol of V3C or V66C α-synuclein were reacted with 300 nmol of 
Alexa Fluor 633 C5 maleimide (Invitrogen) in 20-mM Tris, pH 7.5 for 2 h at room 
temperature and then at 4 C for 18-66 h.  Unreacted cysteines were blocked with 
3 mmol of iodoacetamide (IAA).  Unreacted dye was removed with a two-step 
chromatography process.  First, the bulk of the free dye was removed using a 
HiTrap desalting column (GE Healthcare) in 20-mM phosphate buffer, pH 7.4, 
containing 150-mM NaCl and 15% v/v acetonitrile.  A subsequent, more rigorous, 
purification was performed by using a Superdex200 10/300 column (GE 
Healthcare) in the same buffer.  Fractions with no remaining unreacted dye as 
determined by SDS-PAGE were dialyzed (7000 MWCO cassette, Pierce) into 
water, aliquoted and lyophilized for storage at -80 C.  
The K39C variant of cytochrome c was labeled by using Alexa Fluor 488 
C5 maleimide (Invitrogen) and purified in the same way, except that the second 
chromatography step was not required. 
2.2.4 Fibril Growth 
  α-Synuclein (200- M of the pure or a 9:1 mole:mole mixture of pure and 
Alexa Fluor 633 labeled protein) in 20-mM phosphate buffer (pH 7.4), 150-mM 
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NaCl, and 1-mM EDTA was shaken at 37°C and 225 rpm for 48 h.  Fibril growth 
was quantified via thioflavin-T fluorescence in a 96-well plate using the VersaDoc 
MP imager.  Fibrils were separated from α-synuclein monomers and smaller 
aggregates by centrifugation at 17,000 g for 10 min.  Total protein concentration 
of the resulting supernatant was determined via the Lowry method.  The amount 
of Alexa Fluor 633 was determined via absorbance at 655 nm using a molar 
extinction coefficient of 72,000 M-1cm-1 (9). 
2.3 Results and Discussion 
2.3.1 Purification of α-Synuclein Labeled with Alexa Fluor Requires a 
Multi-Step Approach. 
  Initial attempts at removing free Alexa Fluor from the reaction mixture 
using dialysis, as suggested by the manufacturer, resulted in calculated labeling 
ratios of greater than 100%.  To determine if the excess Alexa Fluor was 
attaching to α-synuclein in a covalent or non-covalent manner, MALDI/MS was 
employed.  This technique was chosen because it can detect Alexa Fluor that is 
covalently attached to α-synuclein, and gives an estimate of the extent of labeling 
by comparing the peak intensities of the unlabeled and labeled protein.  As 
shown in Figure 2.1, only one Alexa Fluor molecule is covalently attached to 
each α-synuclein, and not all of the -synuclein molecules are labeled with dye.  
This indicated that the excess Alexa Fluor was binding to the α-synuclein in a 
non-covalent manner.  Although the manufacturer does not provide the structure 
of Alexa Fluor 633, as seen by the structure of Alexa Fluor 488 (Figure 2.2), all of 
the Alexa Fluor dyes share a similar head-group that contains both aromatic and 
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charged regions.  Since α-synuclein has hydrophobic and charged regions that 
are not protected by secondary structure, it is likely that the dye associates with 
the protein via hydrophobic interactions, electrostatic interactions, or both.  To 
overcome these interactions, the buffer for chromatographic purification was 
changed from water to phosphate-buffered saline with 15% acetonitrile.  Also, 
because such a large excess of dye is required to produce a significant degree of 
labeling, an additional gel-filtration step was added after desalting.  These 
changes yielded a labeling efficiency of 45.0% for the WT:V66C variant (Table 
2.1), which agrees with the calculated ratio from the MS peak intensity data of 
50%.  While labeling efficiencies vary greatly between the variants, the 
differences reflect the batch in which the protein was labeled, not any inherent 
differences in the variants.  Because the labeled protein only made up 
approximately 10% of the total α-synuclein, labeling efficiencies over 10% were 
deemed acceptable for further use. 
2.3.2 Position of Alexa Fluor 633 on α-Synuclein does Not Affect α-
Synuclein Behavior. 
 Wild-type α-synuclein was created with Alexa Fluor attached at either 
cysteine 3 or cysteine 66 to ensure that the position of the Alexa Fluor dye did 
not affect the behavior of the protein in oxidative aggregation reactions (see 
Chapter 3).  These sites were chosen because they are in highly dynamic 
regions of the protein (10) (which decreases the possibility that labeling might 
disrupt native conformation).  As seen in Figure 2.4, regardless of Alexa Fluor 
position, both cytochrome c and H2O2 are required for tyrosine-dependant α-
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synuclein aggregation, and both α-synuclein variants exhibit the same 
aggregation pattern.   
Since position 66 is in the core needed for fibril formation (11), position 3 
was chosen for all subsequent studies.  As seen in Figure 2.5, the fibril pellet of 
unlabeled α-synuclein is white, and the fibril pellet of Alexa Fluor 633 labeled α-
synuclein is blue, indicating that the labeled protein is capable of achieving the 
conformation needed for fibril formation.  Additionally, the unlabeled:labeled ratio 
of protein that was not incorporated into the fibrils was 9:1, the same as the initial 
ratio.  These observations indicate that the Alexa Fluor labeled protein is neither 
preferentially included nor excluded from the fibrils, compared to the unlabeled 
protein. 
2.3.3 Alexa Fluor 488 Only Labels Cytochrome c at the Added Cys39, 
Not at the Endogenous Cys14 or Cys17. 
  Human cytochrome c contains two endogenous cysteine residues at 
positions 14 and 17, which are covalently attached to the heme.  An additional 
cysteine was introduced at position 39 to facilitate Alexa Fluor binding.  This site 
was chosen because the analogous site in yeast cytochrome c has been used 
successfully to label the protein with exogenous molecules without affecting the 
structure or function of the protein (12).  To confirm that the Alexa Fluor reacted 
exclusively with cysteine 39, MALDI/MS was employed following tryptic digestion 
of the protein.  As seen in Figure 2.6, the cysteine-containing fragments 
(residues 14-22 and 39-55) are visible in the unlabeled protein sample.  As 
expected, the 39-55 fragment is barely detectable in the labeled protein sample, 
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while a peak corresponding to the 39-55 fragment bound with Alexa Fluor 488 is 
visible.  Also, no peak is detected for the mass of the 14-22 fragment bound to 
Alexa Fluor 488. 
2.4 Conclusions 
Labeling proteins with Alexa Fluor maleimide dye is an excellent way to 
monitor proteins in a variety of biological and biochemical experiments.  Since 
cysteine is the second-to-least often used amino acid in proteins (13), it is 
possible to singly-label a wide range of proteins, either using an endogenous 
cysteine or by introducing one via site-directed mutagenesis.  The dyes come in 
a range of colors, allowing the simultaneous monitoring of several proteins in a 
single setting.  Although labeling efficiencies depend on reaction conditions, 
adjustment of reaction parameters and the specific dye used can provide labeling 
efficiencies over 80%, which are sufficient for most biological and biochemical 
experiments.  Lastly, a single sample of dye-labeled protein can be analyzed with 
multiple techniques or used in multiple types of experiments, which can greatly 
accelerate method development and data acquisition.  
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Figure 2.1 MALDI/MS of α-synuclein with or without Alexa Fluor 633 label. 
Panel A: WT:V66C.  The mass peak of the unmodified protein is indicated.  
Panel B: WT:V66C labeled with Alexa Fluor 633.  Mass shifts representing the 
binding of iodoacetamide (+~180) or Alexa Fluor 633 (+~1100) to the protein are 
indicated.  Panel C: Y133F:V3C. The mass peak of the unmodified protein is 
indicated.  Panel D: Y133F:V3C labeled with Alexa Fluor 633.  Mass shifts 
representing the binding of iodoacetamide (+~180) or Alexa Fluor 633 (+~1100) 























































Table 2.1 Labeling efficiencies of α-synuclein with Alexa Fluor 633.  
Efficiencies were calculated by dividing total Alexa Fluor concentration (as 
determined by absorbance at 655 nm, using a molar extinction coefficient of 
72,000 M-1cm-1) by total α-synuclein concentration (as determined by the Lowry 
method, see Materials and Methods). 
  







39/125 only 13.4% 
39/133 only 13.9% 
39/136 only 11.6% 
39 only 98.6% 
125 only 58.5% 
133 only 88.7% 





























Figure 2.3 Position of Alexa Fluor tag does not affect covalent aggregation.  
Panel A: Cytochrome c was incubated with H2O2 to form a molecular weight 
marker.  Panel B:Wild-type α-synuclein, with the Alexa Fluor label at position 3 
(V3C, lanes 1-4), or at position 66 (V66C, lanes 5-8) were combined with various 
combinations of cytochrome c and H2O2 for 90 min., separated on a 10-20% 
gradient polyacrylamide gel, and visualized by fluorescence (green, α-synuclein; 
red, cytochrome c). 
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Figure 2.4 Alexa Fluor 633 labeled α-synuclein is capable of forming fibrils.  
Left Tube: fibrils grown from only unlabeled WT α-synuclein.  Right Tube: Fibrils 
grown from 90% unlabeled WT α-synuclein and 10% WT:V3C α-synuclein 





Figure 2.5 MALDI/MS of cytochrome c with or without Alexa Fluor 488 label.  
Top Panel: K39C cytochrome c.  Both cysteine-containing tryptic peptides are 
identifiable, but no masses corresponding to Alexa Fluor-bound peptides are 
detected.  Bottom Panel: K39C cytochrome c labeled with Alexa Fluor 488.  
Alexa Fluor 488 is only found bound to the correct peptide (39-55 fragment). 
[14-22]                  [39-55]  [14-22]+AF488          [39-55]+AF488 
[14-22]                  [39-55]  [14-22]+AF488          [39-55]+AF488 
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Chapter 3 α-Synuclein Conformation Affects its 
Tyrosine-Dependent Oxidative Aggregation 
Reproduced in part with permission from Biochemistry. Copyright 2008 American 
Chemical Society 
3.1 Introduction 
  As discussed in Chapter 1, oxidative stress and the aggregation of α-
synuclein are critical components of Parkinson’s disease.  To study the interplay 
between these two processes, it is essential to choose the proper oxidation 
system.  It must produce tyrosine-dependant covalent aggregation of α-synuclein 
and include components that could come in contact with α-synuclein in cells.  
Based on these criteria, I have chosen the cytochrome c/H2O2, also called the 
peroxidative, system.  Our lab has previously shown that the peroxidative system 
causes tyrosine-dependent covalent aggregation of α-synuclein (1), and in times 
of oxidative stress is it possible that cytochrome c and H2O2 can leak into the 
cytosol (2) aided by pores in the mitochondrial membrane formed by α-synuclein 
(3).  To monitor the behavior of α-synuclein in the peroxidative system, I have 
developed a method of fluorescently labeling and purifying α-synuclein and the 
labeled cytochrome c, which allows simultaneous monitoring of both proteins. 
  Here, I shed light on the process of both peroxidative and non-covalent 
aggregation of α-synuclein and how these forms of aggregation may be related.
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Specifically, I address the role of each tyrosine residue and show how the 
protein’s conformation affects covalent aggregation. 
3.2 Materials and Methods 
 3.2.1 Covalent Aggregation Assays 
  α-Synuclein (100 µM, 9:1 unlabeled:Alexa Fluor labeled for wild-type), 
cytochrome c (10 µM, 1:3 unlabeled:Alexa Fluor labeled) and H2O2 (10 mM) were 
reacted in phosphate-buffered saline (PBS: 20-mM Na2HPO4, pH 7.4, 150-mM 
NaCl) at 37°C for 90 min.  To compensate for the varying Alexa Fluor labeling 
efficiencies of α-synuclein variants, the amount of labeled α-synuclein was 
adjusted so that each variant had the same total fluorescence as the wild-type 
control sample.  Control experiments show that this adjustment does not affect 
the conclusions. For the cytochrome c control reaction, 100-µM cytochrome c 
(100% Alexa Fluor labeled) and 10-mM H2O2 were reacted under the same 
conditions as above. Samples were resolved by electrophoresis on 10-20% 
gradient sodium dodecyl sulfate (SDS) polyacrylamide gels (PAG) (Criterion, 
BioRad) for 75 min at 200 V.  Gels were analyzed for fluorescence with a 
VersaDoc MP imager (BioRad) and for total protein content with Coomassie Blue 
staining. 
 3.2.2 Fibril Formation 
  α-Synuclein (200 µM) in PBS with 1-mM EDTA was shaken at 37°C and 
225 rpm for 48 h.  Fibril growth was quantified via thioflavin-T fluorescence in a 
96-well plate by using the VersaDoc MP imager.  Cytochrome c (final 
concentration 20 µM) and H2O2 (final concentration 20 mM) were added to the 
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reaction either at the beginning or at the end of the shaking period.  Fibrils were 
separated from α-synuclein monomers and smaller aggregates by centrifugation 
at 1.7 x 104 g for 10 min.  Fibrils (pellet) and small aggregates (supernatant) were 
treated with SDS and boiled for 10 min before being analyzed by SDS-PAGE as 
described above. 
3.3 Results 
 3.3.1 Alexa Fluor Labeling and Tyrosine-Dependent α-Synuclein 
Covalent Aggregation. 
  The wild-type protein and the variant containing no tyrosines were 
combined with cytochrome c and H2O2. Figure 3.1A shows the results of the 
reaction between cytochrome c and H2O2 as a standard.  As shown in Figure 
3.1B, cytochrome c and H2O2, as well as the tyrosines in α-synuclein, are 
required for oxidative aggregation.  This result agrees with our previous work, 
which used Coomassie Blue and anti-α-synuclein antibody detection (1).  In all 
peroxidative aggregation reactions, a population of α-synuclein monomer is left 
unreacted, even after exposure to additional cytochrome c and H2O2.  This result 
indicates that some portion of the α-synuclein is rendered incapable of covalent 
aggregation after exposure to cytochrome c and H2O2.  This effect has also been 
seen when human neuroglobin is exposed to peroxide (4).  Alexa Fluor labels on 
α-synuclein and cytochrome c allow facile detection of peroxidative covalent 
aggregation of α-synuclein. 




  To examine the chemical reactivity of each tyrosine, four variants, each 
containing only one tyrosine, were reacted with cytochrome c and H2O2.  Our 
conditions do not promote non-covalent aggregation of α-synuclein. Figure 3.2A 
shows the reaction between cytochrome c and H2O2 as a standard.  Figure 3.2B 
shows the differing ability of each tyrosine to form inter-molecular dityrosine 
bonds.  Tyrosines 133 and 136 are the most reactive, as shown by distinct dimer 
formation and little α-synuclein degradation. Streaking of the α-synuclein 
because of random backbone cleavage and large amounts of degraded α-
synuclein indicate that tyrosine 125 is less able to accept a radical from 
cytochrome c.  Lack of α-synuclein dimer and large amounts of degradation 
indicate that tyrosine 39 is the least reactive. Tyrosine 39 is so unreactive that it 
does not form an intact heterodimer with cytochrome c as seen in the other 
variants.  Instead, some of the free radicals generated cause degradation of the 
heterodimer.  In summary, the chemical reactivities of the tyrosines in α-
synuclein to form dityrosines increase in the following order: 39, 125, 133/136. 
 3.2.3 Tyrosine 39 is Essential for Wild-Type-Like Covalent Aggregation 
of Native α-Synuclein. 
  To determine how each tyrosine contributes to covalent aggregation, 
seven variants, each containing two or three tyrosines, were reacted with 
cytochrome c and H2O2.  The conditions used do not promote non-covalent 
aggregation of α-synuclein. Figure 3.3A shows the reaction between cytochrome 
c and H2O2 as a standard.  Figure 3.3B shows the participation of each tyrosine 
in oxidative aggregation.  When tyrosine 125, 133, or 136 is removed (Figure 
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3.3B, lanes 3-5), covalently aggregated species are populated in the same 
manner as for the wild-type protein (lane 1).  When the least reactive tyrosine, 
tyrosine 39, is removed (Figure 3.3B, lane 2), even-numbered aggregates (dimer, 
tetramer, and perhaps hexamer and octamer) are favored over the trimer.  In 
general, more uniform covalent aggregate populations are observed when α-
synuclein has at least one tyrosine at each end.  This observation is supported 
by the data in Figure 3.3C, where variants with tyrosine 39 and one other 
tyrosine are examined. 
 3.2.4 Changes in Covalent Aggregation Induced by a Denaturant. 
  If α-synuclein were totally disordered, one would expect that wild-type-like 
covalent aggregation could be achieved if any two tyrosines are present.  
However, as shown in Figure 3.3, tyrosine 39 is essential for wild-type-like 
covalent aggregation.  To determine if protein conformation was the basis of this 
observation, wild-type α-synuclein or the variant with tyrosine 39 removed were 
reacted with cytochrome c and H2O2 in the presence and absence of the 
denaturant, guanidine hydrochloride (300 mM).  A control experiment (not 
shown) illustrates that 300 mM guanidine hydrochloride does not affect radical 
formation as assessed by the bands formed in cytochrome c covalent 
aggregation with and without guanidine hydrochloride.  Coomassie Blue staining 
was used because guanidine hydrochloride interferes with Alexa Fluor 
fluorescence. In the presence of guanidine hydrochloride (Figure 3.4B-C, lane 2), 
large covalent aggregates are more heavily favored for both wild-type and Y39F 
α-synuclein compared to the reaction in the absence of guanidine hydrochloride 
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(Figure 3.4B-C, lane 1). In agreement with NMR-based experiments, these data 
show that α-synuclein must have some structure that can be destroyed by a 
denaturant (5). 
 3.2.5 Fibril Formation and Oxidative Aggregation. 
  To determine if covalent aggregation affects the conformation required for 
non-covalent fibril formation, fibrils were grown from the wild-type protein.  
Coomassie Blue staining was used because the fibril growth conditions interfere 
with Alexa Fluor fluorescence. As a control, either cytochrome c or H2O2 were 
added either at the start or end of fibril growth.  In each of these conditions, no 
covalent aggregates were detected in the supernatant or in the fibrils (data not 
shown).  Figure 3.5B shows the effects of exposing the fibrillization reaction to 
cytochrome c and H2O2 at the beginning or at the end of fibril growth. When 
peroxidation is introduced after 24 h of fibril growth (lanes 3 and 4), the covalent 
aggregates are observed in both the supernatant and the fibrils, and a large fibril 
pellet is observed.  When peroxidation is introduced early, almost no fibrils are 
formed (as indicated by a miniscule pellet) and there is nearly a complete 
absence of covalent aggregates (lane 2).  Instead, nearly all of the covalent 
aggregates are found in the supernatant (lane 1).  Similar results are obtained for 
the variant containing only the tyrosine 39 to phenylalanine mutation (although 
the yield of fibrils is lower).  
3.4 Discussion 
  The present studies examine the role of α-synuclein conformation in its 
peroxidative aggregation. The conformations of this intrinsically disordered 
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protein have been characterized by  NMR, and the shape shown in Figure 1B is 
just one of an ensemble of collapsed conformations adopted by α-synuclein (5).  
While the protein does not have a rigid secondary structure, these conformations 
have similar characteristics, namely that the charged termini collapse onto the 
hydrophobic core.  In each conformation, the region surrounding tyrosine 39 
abuts the core and C-teminus.  This contact keeps tyrosine 39 partially protected 
from the solvent, which accounts for its low reactivity (Figure 3.2).  NMR-detected 
amide-proton exchange experiments also show that tyrosine 39 is protected from 
the solvent, as indicated by its low exchange rate (6). In each conformation, the 
region surrounding tyrosine 125 contacts three other regions (residues 11-13, 30-
75, and 78-99) (7).  Tyrosine 125 is in a region of increased rigidity compared to 
the rest of the protein (5, 7, 8), although the C-terminus as a whole is 
comparatively mobile.  This synergy of rigidity and flexibility accounts for the 
decreased reactivity of tyrosine 125 compared to tyrosines 133 and 136, and its 
increased reactivity compared to tyrosine 39 (Figure 3.2). 
  The collapsed conformation of α-synuclein explains why at least one 
tyrosine on each end of the protein is required to maintain a distribution of 
covalent aggregates similar to that observed for the wild-type protein (Figure 7A).  
When C-terminal tyrosines from two α-synuclein monomers react, the collapsed 
conformation sterically hinders the two remaining C-terminal tyrosines from 
reacting (Figure 3.6B and 3.6C).  Without a tyrosine near the N-terminus, i.e. 
tyrosine 39, dimers are favored (Figure 3.6B), but once a sufficient population of 
dimers accumulates, they tend to form tetramers, hexamers, and higher-order 
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even-numbered aggregates (Figure 3.6C). The lower reactivities of tyrosines 39 
and 125 (Figure 3.2) explain why variants with only these tyrosines (Figure 3.3C, 
lane 1) tend to form fewer higher-order covalent aggregates.  When α-synuclein 
is denatured with guanidine hydrochloride, an N-terminal tyrosine is no longer 
needed for wild-type-like covalent aggregation (Figure 3.6D) because the three 
C-terminal tyrosines are more accessible.  
  α-Synuclein must undergo a folding event to form an aggregation nucleus 
(9) before forming fibrils (Figure 3.6E).  Covalently cross-linking the protein’s 
tyrosines prevents it from folding properly, so that, as shown in Figure 3.5, 
covalent aggregates are not incorporated into fibrils.  In addition, when oxidation 
is introduced at the start of the fibrillization process, little to no fibril growth is 
observed because the concentration of monomer is too low to allow fibrillization 
in the time frame of the experiment.  Once fibrils have assembled (Figure 3.6E), 
however, the termini are stacked (10) so that the tyrosines are solvent-exposed 
and accessible for oxidative cross-linking.  While tyrosine 39 is essential for fibril 
formation (11), an N-terminal tyrosine is not required for covalent aggregation 
within fibrils. This observation is similar to that which is observed when the 
protein is denatured by guanidine hydrochloride. In summary, my data indicate 
that both covalent and non-covalent aggregation of α-synuclein depend on its 
conformation and suggest that covalent aggregation occurs in Lewy bodies after 
























Figure 3.1 Alexa Fluor labeling detects peroxidative aggregation. 
Panel A: Cytochrome c was incubated with and without H2O2.  Panel B: α-
Synuclein , either the wild-type protein with the Alexa Fluor label at position 3 
(WT, lanes 1-4), or a no tyrosine variant with the Alexa Fluor label at position 3 
(noY, lanes 5-8) were combined with various combinations of cytochrome c and 
H2O2 for 90 min., separated on a 10-20% gradient polyacrylamide gel, and 
visualized by fluorescence (green, α-synuclein; red, cytochrome c).   
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Figure 3.2 Every tyrosine in α-synuclein is reactive, but to varying extents. 
Panel A: Cytochrome c was incubated with H2O2.  Panel B: The wild-type 
protein (WT) and single tyrosine-containing variants of α-synuclein  were reacted 
with cytochrome c and H2O2 for 90 minutes, and treated as described in the 



























































Figure 3.3 At least one tyrosine on each end is required for wild-type-like 
covalent aggregation of collapsed α-synuclein.  Panel A: Cytochrome c was 
incubated with H2O2.  Panel B: The wild-type protein and variants containing 
three tyrosines or Panel C: two tyrosines were reacted with cytochrome c and 
H2O2 for 90 minutes, and treated as described in the caption to Figure 2.  Legend 
at top indicates which tyrosines are present in each variant. α-Synuclein  
aggregate species are indicated on the right. 
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Figure 3.4 Tyrosine 39 is not required for full aggregation of denatured α-
synuclein.  Panel A: Molecular weight marker.  Panel B: The wild-type protein 
(WT) and Panel C: the variant with tyrosine 39 removed (Y39F) were reacted 
with cytochrome c and H2O2 in the presence (lanes 2) or absence (lanes 1) of 
guanidine hydrochloride. Samples were separated on a 10-20% gradient 
polyacrylamide gel, and visualized by Coomassie Blue staining. 
  




















































Figure 3.5 Oxidative aggregation interferes with fibril formation.  Panel A: 
Molecular weight marker.  Panel B: The wild-type protein was reacted with 
cytochrome c and H2O2 before (lanes 1 and 2) or after (lanes 3 and 4) fibril 
formation.  Fibrils were isolated by centrifugation. Fibrils (lanes 2 and 4) and the 
supernatant (lanes 1 and 3) were boiled with SDS, separated on 10-20% 
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Figure 3.6 α-Synuclein conformation and covalent aggregation.  Panel A: 
When α-synuclein adopts a collapsed conformation, various covalently 
aggregated species are more equally populated when at least one tyrosine is 
present on each end of the protein . Panels B and C: Even-numbered 
aggregates are favored when tyrosine 39 is removed.  Panel D: When α-
synuclein is completely disordered, the largest aggregate species are favored, 
even if tyrosine 39 is removed.  Panel E: Covalent α-synuclein aggregates are 
unable to fold into the beta-sheet aggregation nucleus, but once the folded 
monomers have assembled into protofibrils, the termini are stacked, allowing 
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Chapter 4 Progress Towards Neuronal Microinjection 
of Aggregated α-Synuclein 
4.1 Introduction 
  As described in Chapter 1, the aggregation of α-synuclein is a critical but 
poorly understood process in Parkinson’s disease.  Currently it is not known 
which aggregated form is most toxic in vivo, but in vitro evidence points towards 
the protofibril, particularly the annular or ring-shaped form (1).  Some studies 
have shown that α-synuclein aggregates are toxic to cells, but these studies are 
insufficient for several reasons (2-4).  In all experiments, cells were made to 
express α-synuclein by transfection, in which the level of protein expression is 
not controlled.  This process does not lend itself to quantitative analysis of 
aggregate toxicity because a controlled amount of aggregate cannot be 
introduced to the cells.  Also, these experiments exposed the cells to a mixture of 
aggregate species, not specific aggregates.  Furthermore, these experiments did 
not address the question of whether oxidative stress is a cause of aggregation, a 
product of aggregation, or both. 
Neuronal microinjection is an ideal technique to combat these problems 
(5).  Briefly, specific neurons are harvested from neonatal mice and cultured on 
adherent plates.  Protein samples are injected into individual cells and cell
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viability is measured as a function of time.  The components of the culture media 
and/or injection sample can be modified as required to mimic cellular processes 
such as oxidative stress or dopamine processing.  Overall, neuronal 
microinjection allows measurements of the concentration-dependant toxicity of 
individual aggregate species under a variety of cellular conditions.   
When beginning a new protocol, especially one that involves animals, it is 
imperative that all controls and procedures be established before data collection 
begins.  To that end, this chapter details the progress toward sample preparation 
and oxidative stress induction and detection. 
4.2 Sample Preparation 
 4.2.1 Cell Adherence 
  Neuronal microinjection is usually conducted with cells adhered to a 35-
mm plastic culture dish with collagen.  Glass-bottomed culture dishes are 
required because quantitative fluorescence analysis is needed to measure 
oxidative stress in the cells.  Three types of plates were tested: freshly collagen-
coated, collagen-coated by the manufacture (MatTek, Ashland, Massachusetts), 
and freshly lysine-coated.  Superior cervical ganglion neurons only adhere to the 
freshly collagen-coated plates.  Also, if freshly-coated plates are stored for more 
than a few hours, even at 4°C, neurons no longer adhere to them.   
  Interestingly, even though cells adhere to freshly collagen-coated plates, 
the collagen itself does not adhere well to the glass of the plate.  Typically, the 
collagen is applied to the plate via a disposable dropper pipette, which does not 
allow consistent deposition.  Also, the glass-bottomed plates have a smaller area 
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than the plastic plates, so one drop of collagen makes a thicker layer on glass 
that may not dry evenly, leading to poor adherence.  In addition, it is critical that 
the collagen layers are uniform so that the cells adhere in the horizontal plane for 
imaging.  To address these issues, the collagen was applied in two layers using 
volumes of either of either 50 or 25 µL.  The plates were allowed to air-dry for at 
least 2 hours between applications.  The 50-µL application is too thick to adhere 
properly to the glass, but the 25-µL application adheres well.  Although the two-
layer application increases adherence of the collagen layer, it also causes 
uneven collagen that disrupts cell adhesion.  In the end, one 25-µL collagen 
layer, carefully spread with a glass stir rod on a glass-bottom culture dish, 
provides the best combination of collagen adhesion, collagen uniformity, and cell 
adhesion. 
 4.2.2 Growth Medium 
  Initially, cells were grown in AM50 medium [minimum essential medium 
(MEM) without phenol red (Gibco, Invitrogen) supplemented with 10% fetal 
bovine serum, 2-µM uridine (Sigma, St. Louis, Missouri), 2-µM fluorodeoxyuridine 
(Sigma), 100 µg/mL penicillin (Gibco), 100 µg/mL streptomycin (Gibco), and 50 
ng/mL murine nerve growth factor 7S (Promega, Madison, Wisconsin)].  This 
medium contains no antioxidants, and therefore the cells are susceptible to 
oxidative stress, especially when being transported between labs.  To correct 
this, the AM50 growth medium was supplemented with 50-µM α-tocopherol 




Oxidative stress induction and detection are discussed in more detail later, 
but briefly, the cells are grown in the test medium for 4-7 days, and then washed 
thoroughly with MEM.  Oxidative stress is induced in the positive control plates, 
which are washed again with MEM before oxidative stress detection.  As seen in 
Figure 4.1, the addition of vitamin E gives mixed results on measuring oxidative 
stress.  In AM50 medium, the variance between samples of the same type is 
small (0-0.8%), the variance within one sample is small (0-2.5%), and the values 
of the negative control (0%) and positive control (6.0-6.8%) are statistically 
different.  However, the difference between the positive and negative controls is 
small.  Conversely, in medium supplemented with vitamin E, the variance 
between samples of the same type is large (9%), the variance within one sample 
is large (1.8-13.3%), and the values of the negative control (1.8%) and positive 
control (3.9-12.9%) are statistically the same.  This large variance may be due to 
vitamin E’s high hydrophobicity; it may not dissolve fully in the AM50 medium, 
causing cells to receive varying amounts of the antioxidant.  However, several 
hydrophilic antioxidants, including ascorbic acid (vitamin C), phenol red, and 
trolox (a water-soluble form of vitamin E), may prove effective in preventing 
oxidative stress during the growth of the neurons and thereby allow a greater 
response to induced oxidative stress in the positive controls. 
4.2.3 Alexa Fluor Labeling of α-Synuclein 
 As discussed in Chapter 2, Alexa Fluor labeling of α-synuclein is an 
efficient method for fluorescently tagging the protein.  In this experimental design, 
there are several parameters to consider when choosing the specific Alexa Fluor 
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dye.  The three fluorescent microscopes used for microinjection, cell counting, 
and oxidative stress measurement/cell imaging all have the standard blue, green, 
and red filter sets, albeit they have a slightly different range on each microscope.  
As described in more detail below, the blue channel is used for Hoechst dye (a 
DNA marker) and the green for 5-(and-6)- carboxy-2′,7′-dichlorodihydro-
fluorescein diacetate (an oxidative stress fluorogenic marker), leaving the red 
channel for Alexa Fluor.  Of the Alexa Fluor maleimides, two (Alexa Fluor 555 
and Alexa Fluor 568) are compatible with the red channel.  Both dyes label α-
synuclein to an acceptable degree (~90% for Alexa Fluor 555 and ~75% for 
Alexa Fluor 568).  Alexa Fluor 568 was ultimately chosen for its higher 
fluorescence intensity on the cell counting microscope because cell counting is 
done by eye. 
4.3 Oxidative Stress Induction and Detection 
4.3.1 Inducing Oxidative Stress for Positive Control 
  Tert-butyl-hydroperoxide (TBHP) was used as a positive control for 
oxidative stress-induction.  I noticed a decrease in the number of oxidative 
stress-positive cells in the positive control plates with time.  To determine if the 
age or concentration of TBHP was a factor in the decrease, I compared the 
original sample (approximately 6 months old) with a newly prepared 100 mM-
stock solution, both diluted to a working solution at the original concentration 
(100 μM) and a higher concentration (200 μM).  As seen in Figure 4.2, both the 
age of the stock solution and the concentration of the working solution play a role 
in the amount of oxidative stress induced.  The older TBHP sample induced 
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oxidative stress in only 0.4-1.1% of the cells, compared to 1.6-3.1% using the 
freshly prepared sample and 9.0-9.8% at the higher concentration.  This same 
sample was used 25 days later (the AM50 data in Figure 4.2) and only induced 
oxidative stress in 6.0-6.8% of the cells.  These observations indicate that TBHP 
has a short shelf life.  A fresh stock solution must be prepared for every 
experiment the stock should not be frozen (7). 
 4.3.2 Fluorogenic Oxidative Stress Marker Selection 
  Dozens of fluorogenic markers that detect various forms of oxidative 
stress are commercially available.  For the purposes of these experiments, the 
marker must possess the following criteria: 1) detect oxidative stress in living 
cells, 2) emit fluorescence detectable with the filter sets on the available 
microscopes, 3) have a proportional response to the amount of oxidative stress 
and 4) ,ideally, detect a wide range of reactive oxygen species.  Based on the 
first parameter, six markers were chosen for study. 
  As seen in Table 4.1, diphenyl-1-pyrenylphosphine fails criterion 2 
because no fluorescence was detected in the negative control cells, the positive 
control cells, or the background.  MitoTracker, reduced MitoTracker, 
RedoxSensor Red, and Amplex Red all fail criterion 3 because the positive and 
negative controls have approximately the same number of oxidative stress-
positive cells.  Ultimately, Image-iT [5- (and 6-) carboxy-2′,7′-dichlorodihydro-
fluorescein diacetate] was chosen because it possesses all of the necessary 
criteria. 
 4.3.3 Staining Procedure 
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To measure oxidative stress in the cells, the cells must be transported 
from the growth lab to the imaging lab, an approximately 15-min walk across 
campus.  Initially, the cells were transported in a commercially prepared 
hibernation medium (Hibernate E, Brain Bits, Springfield, Illinois) to preserve 
them in the ambient CO2 conditions.  The cells were stained with Image-iT and 
Hoechst dye at the imaging lab.  They were then washed with MEM before 
imaging with an inverted fluorescence microscope (DMIRB, Leica, Wetzlar, 
Germany) fitted with an OrcaER camera (Hamamatsu, Sewickley, Pennsylvania) 
and SimplePCI software (Hamamatsu).  Although a quantitative analysis could 
not be performed due to a lack of background correction, a qualitative analysis 
confirmed the prior assessment that TBHP induces Image-iT detectable oxidative 
stress (Figure 4.3). 
Staining the cells at the imaging facility is difficult due to lack of proper 
equipment and space.  Also, the phenol red present in the hibernation medium 
may counteract the induced oxidative stress.  For the second test, the cells were 
stained in the growth lab with Image-iT diluted in MEM, transported to the 
imaging lab in the same medium, then washed and imaged as described above, 
with the addition of the proper background correction controls.  Surprisingly, the 
negative controls showed a high level of stress and the positive controls a low 
level (Figure 4.4).  It is unclear whether exposure to low CO2 levels during 
transport or the staining procedure itself is responsible for this effect.   
For the final experiment, half of the cells were stained in the growth lab 
with Image-iT diluted in hibernation medium lacking phenol red and half were 
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transported to the imaging lab in hibernation medium lacking phenol red and then 
stained.  Then all cells were washed and imaged as described above.  As shown 
in Figure 4.5, transportation in hibernation medium lacking phenol red followed 
by staining with Image-iT at the imaging facility results in a low response in the 
negative control and a high response in the positive control.  These staining 
procedures were used for all subsequent experiments, including the data shown 
in Figures 4.1 and 4.2. 
4.4 Conclusions 
  Now that the parameters have been established for growing neurons, 
labeling α-synuclein, and inducing and measuring oxidative stress within cells, 
the final parameter to set is the production and isolation of α-synuclein aggregate 
species.  As shown in Chapters 2 and 3, I have already established a procedure 
for growing and purifying the fibril form.  Fortunately, many procedures to 
produce both spherical and annular protofibrils have been described in the 
literature (8-11).  I am confident that once a procedure for generating aggregates 
has been established, neuronal microinjection will prove to be a powerful tool to 
determine the toxicity of α-synuclein aggregates and what role oxidative stress 





4.5 Figures and Tables 
 
 
Figure 4.1 Vitamin E-supplemented growth media modulates neuronal 
response to oxidative stress.  Superiour cervical ganglion cells were grown in 
AM50 media with or without 50-μM vitamin E for 4 days.  The cells were washed 
with MEM and the positive control cells were stressed with 200-μM TBHP in 
MEM for 180 min.  Cells were washed with MEM, transported in hibernation 
medium without phenol red, and stained with Image-iT.  While the vitamin E 
facilitates a difference between the negative and positive controls, it also causes 
a high variance between samples. Error bars represent the standard deviation of 
nine images collected per sample.  An average of 230 cells were counted per 
image.  (Blue bars, negative control; Red bars, positive control; light and dark are 









































Figure 4.2 Age of stock solution and concentration of working solution 
affect the ability of TBHP to induce oxidative stress.  Cells were stressed 
with either old (6 months) TBHP stock at 100 μM working concentration, fresh 
TBHP stock at 100 μM working concentration, or fresh TBHP stock at 200 μM 
working concentration.  The cells were washed with MEM, transported in 
hibernation medium without phenol red, and stained with Image-iT.  Fresh TBHP 
and increased TBHP concentration both improve the effectiveness of TBHP at 
inducing oxidative stress.Error bars represent the standard deviation of three 
images collected per sample.  An average of 70 cells were counted per image.  







































Table 4.1 Fluorogenic markers to detect oxidative stress. 
ROS, reactive oxygen species; Cells, amount of fluorescence detected in cells; 

































































































































Figure 4.4 Transporting cells in staining solution reverses the expected 
results.  Positive control cells were stressed with 200-μM TBHP in MEM for 180 
minutes.  All cells were washed with MEM, stained with Image-iT diluted in MEM, 
and transported to imaging lab.  The negative controls show a high level of stress 
and the positive controls a low level, which contradicts what is expected.  An 
average of 200 cells were counted per image.  (Blue bars, negative control; Red 



































Figure 4.5 Transport in hibernation media and staining immediately prior to 
imaging are crucial for proper oxidative stress detection.  Cells were either 
stained in the growth lab with Image-iT diluted in hibernation medium lacking 
phenol red (Growth Lab) or transported to the imaging lab in hibernation medium 
lacking phenol red and then stained (Imaging Lab).  Staining after transport is 
essential for accurate oxidative stress detection. Error bars represent the 
standard deviation of three images collected per sample.  An average of 154 
cells were counted per image.  (Blue bars, negative control; Red bars, positive 
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